Parmax Pharma Limited

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MEDPLUS.NS has a market cap of 99.3B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MEDPLUS.NS trades at ₹839.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MEDPLUS.NS's P/E ratio is 47.93. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MEDPLUS.NS's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is more volatile compared to MEDPLUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MEDPLUS.BO has a market cap of 99.3B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MEDPLUS.BO trades at ₹837.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MEDPLUS.BO's P/E ratio is 47.90. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MEDPLUS.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is more volatile compared to MEDPLUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDPLUS.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, GUJTHEM.BO has a market cap of 27.4B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while GUJTHEM.BO trades at ₹227.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas GUJTHEM.BO's P/E ratio is 57.43. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to GUJTHEM.BO's ROE of +0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to GUJTHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GUJTHEM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, KPL.BO has a market cap of 14.4B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while KPL.BO trades at ₹1,306.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas KPL.BO's P/E ratio is 25.53. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to KPL.BO's ROE of +0.21%. Regarding short-term risk, PARMAX.BO is less volatile compared to KPL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KPL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SHUKRAPHAR.BO has a market cap of 14B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SHUKRAPHAR.BO trades at ₹30.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SHUKRAPHAR.BO's P/E ratio is -159.65. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SHUKRAPHAR.BO's ROE of +0.47%. Regarding short-term risk, PARMAX.BO is more volatile compared to SHUKRAPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SHUKRAPHAR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, FREDUN.BO has a market cap of 9.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while FREDUN.BO trades at ₹1,671.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas FREDUN.BO's P/E ratio is 24.20. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to FREDUN.BO's ROE of +0.23%. Regarding short-term risk, PARMAX.BO is more volatile compared to FREDUN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check FREDUN.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SASTASUNDR.NS has a market cap of 8.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SASTASUNDR.NS trades at ₹256.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SASTASUNDR.NS's P/E ratio is 33.56. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SASTASUNDR.NS's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to SASTASUNDR.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SASTASUNDR.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SASTASUNDR.BO has a market cap of 8.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SASTASUNDR.BO trades at ₹261.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SASTASUNDR.BO's P/E ratio is 33.51. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SASTASUNDR.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to SASTASUNDR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SASTASUNDR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ANUHPHR.BO has a market cap of 7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ANUHPHR.BO trades at ₹67.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ANUHPHR.BO's P/E ratio is 16.80. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ANUHPHR.BO's ROE of +0.13%. Regarding short-term risk, PARMAX.BO is more volatile compared to ANUHPHR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ANUHPHR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, BPLPHARMA.BO has a market cap of 6.5B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while BPLPHARMA.BO trades at ₹900.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas BPLPHARMA.BO's P/E ratio is -21.98. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to BPLPHARMA.BO's ROE of -0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to BPLPHARMA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BPLPHARMA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ALBERTDA.BO trades at ₹1,084.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ALBERTDA.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to ALBERTDA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ALBERTDA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SUDARSHAN.BO has a market cap of 5.8B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SUDARSHAN.BO trades at ₹24.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SUDARSHAN.BO's P/E ratio is 28.88. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SUDARSHAN.BO's ROE of +0.16%. Regarding short-term risk, PARMAX.BO is less volatile compared to SUDARSHAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SUDARSHAN.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SGRL.BO has a market cap of 5.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SGRL.BO trades at ₹420.05.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SGRL.BO's P/E ratio is 31.36. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SGRL.BO's ROE of +0.13%. Regarding short-term risk, PARMAX.BO is less volatile compared to SGRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SGRL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PRAVEG.BO has a market cap of 5.2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PRAVEG.BO trades at ₹183.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PRAVEG.BO's P/E ratio is -136.34. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PRAVEG.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to PRAVEG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PRAVEG.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, JENBURPH.BO has a market cap of 4.5B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while JENBURPH.BO trades at ₹955.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas JENBURPH.BO's P/E ratio is 13.76. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to JENBURPH.BO's ROE of +0.19%. Regarding short-term risk, PARMAX.BO is less volatile compared to JENBURPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check JENBURPH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VIKRAMTH.BO has a market cap of 4.4B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VIKRAMTH.BO trades at ₹136.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VIKRAMTH.BO's P/E ratio is 12.92. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VIKRAMTH.BO's ROE of +0.28%. Regarding short-term risk, PARMAX.BO is less volatile compared to VIKRAMTH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VIKRAMTH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, INFINIUM.NS has a market cap of 3.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while INFINIUM.NS trades at ₹192.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas INFINIUM.NS's P/E ratio is 33.06. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to INFINIUM.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check INFINIUM.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TLL.BO has a market cap of 3.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TLL.BO trades at ₹268.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TLL.BO's P/E ratio is 20.80. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TLL.BO's ROE of +0.24%. Regarding short-term risk, PARMAX.BO is less volatile compared to TLL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TLL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ZENOTECH.BO has a market cap of 2.2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ZENOTECH.BO trades at ₹34.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ZENOTECH.BO's P/E ratio is 64.35. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ZENOTECH.BO's ROE of +0.03%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENOTECH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENOTECH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, BDH.BO has a market cap of 2.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while BDH.BO trades at ₹352.70.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas BDH.BO's P/E ratio is 19.78. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to BDH.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is more volatile compared to BDH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check BDH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, KERALAYUR.BO has a market cap of 2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while KERALAYUR.BO trades at ₹157.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas KERALAYUR.BO's P/E ratio is -8.41. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to KERALAYUR.BO's ROE of -1.45%. Regarding short-term risk, PARMAX.BO is less volatile compared to KERALAYUR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KERALAYUR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TRANSCHEM.BO has a market cap of 2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TRANSCHEM.BO trades at ₹162.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TRANSCHEM.BO's P/E ratio is 67.08. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TRANSCHEM.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to TRANSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TRANSCHEM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, GENNEX.BO has a market cap of 1.9B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while GENNEX.BO trades at ₹7.13.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas GENNEX.BO's P/E ratio is 10.82. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to GENNEX.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to GENNEX.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GENNEX.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, AMBALALSA.BO has a market cap of 1.9B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while AMBALALSA.BO trades at ₹24.27.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas AMBALALSA.BO's P/E ratio is 18.47. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to AMBALALSA.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to AMBALALSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AMBALALSA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SYSCHEM.BO has a market cap of 1.9B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SYSCHEM.BO trades at ₹41.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SYSCHEM.BO's P/E ratio is 29.09. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SYSCHEM.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to SYSCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SYSCHEM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, QUESTLAB.NS has a market cap of 1.8B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while QUESTLAB.NS trades at ₹104.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas QUESTLAB.NS's P/E ratio is 13.09. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to QUESTLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check QUESTLAB.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while OXYGENTAPH.BO trades at ₹48.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas OXYGENTAPH.BO's P/E ratio is -9.89. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to OXYGENTAPH.BO's ROE of +0.65%. Regarding short-term risk, PARMAX.BO is less volatile compared to OXYGENTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check OXYGENTAPH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SANJIVIN.BO has a market cap of 1.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SANJIVIN.BO trades at ₹132.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SANJIVIN.BO's P/E ratio is 21.21. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SANJIVIN.BO's ROE of +0.22%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANJIVIN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANJIVIN.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, AUROLAB.BO has a market cap of 1.7B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while AUROLAB.BO trades at ₹265.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas AUROLAB.BO's P/E ratio is 52.56. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to AUROLAB.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to AUROLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check AUROLAB.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PARNAXLAB.BO has a market cap of 1.5B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PARNAXLAB.BO trades at ₹128.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PARNAXLAB.BO's P/E ratio is 12.20. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PARNAXLAB.BO's ROE of +0.15%. Regarding short-term risk, PARMAX.BO is more volatile compared to PARNAXLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check PARNAXLAB.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, NATCAPSUQ.BO has a market cap of 1.4B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while NATCAPSUQ.BO trades at ₹144.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas NATCAPSUQ.BO's P/E ratio is -7.51. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to NATCAPSUQ.BO's ROE of -0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to NATCAPSUQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check NATCAPSUQ.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PANCHSHEEL.BO has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PANCHSHEEL.BO trades at ₹90.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PANCHSHEEL.BO's P/E ratio is 11.01. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PANCHSHEEL.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANCHSHEEL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANCHSHEEL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, CORALAB.BO has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while CORALAB.BO trades at ₹370.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas CORALAB.BO's P/E ratio is 9.25. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to CORALAB.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to CORALAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CORALAB.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SOTAC.NS has a market cap of 1.3B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SOTAC.NS trades at ₹109.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SOTAC.NS's P/E ratio is 14.86. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to SOTAC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SOTAC.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SMRUTHIORG.BO has a market cap of 1.2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SMRUTHIORG.BO trades at ₹96.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SMRUTHIORG.BO's P/E ratio is 26.59. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SMRUTHIORG.BO's ROE of +0.07%. Regarding short-term risk, PARMAX.BO is less volatile compared to SMRUTHIORG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SMRUTHIORG.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, KIMIABL.BO has a market cap of 1.2B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while KIMIABL.BO trades at ₹23.55.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas KIMIABL.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to KIMIABL.BO's ROE of +1.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to KIMIABL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KIMIABL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TYCHE.BO trades at ₹99.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TYCHE.BO's P/E ratio is 15.67. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TYCHE.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to TYCHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TYCHE.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PHARMAID.BO trades at ₹27.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PHARMAID.BO's P/E ratio is -5.91. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PHARMAID.BO's ROE of -0.24%. Regarding short-term risk, PARMAX.BO is less volatile compared to PHARMAID.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PHARMAID.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, LACTOSE.BO has a market cap of 984.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while LACTOSE.BO trades at ₹80.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas LACTOSE.BO's P/E ratio is 20.26. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to LACTOSE.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to LACTOSE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check LACTOSE.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MERCURYLAB.BO has a market cap of 876M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MERCURYLAB.BO trades at ₹700.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MERCURYLAB.BO's P/E ratio is 18.56. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MERCURYLAB.BO's ROE of +0.09%. Regarding short-term risk, PARMAX.BO is less volatile compared to MERCURYLAB.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MERCURYLAB.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MAKERSL.BO has a market cap of 858.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MAKERSL.BO trades at ₹135.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MAKERSL.BO's P/E ratio is 70.31. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MAKERSL.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is more volatile compared to MAKERSL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check MAKERSL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, DENISCHEM.BO has a market cap of 835.5M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while DENISCHEM.BO trades at ₹56.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas DENISCHEM.BO's P/E ratio is 9.59. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to DENISCHEM.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to DENISCHEM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DENISCHEM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SOURCENTRL.BO has a market cap of 715.1M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SOURCENTRL.BO trades at ₹108.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SOURCENTRL.BO's P/E ratio is 25.66. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SOURCENTRL.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is less volatile compared to SOURCENTRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SOURCENTRL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, CONCORD.BO has a market cap of 699.6M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while CONCORD.BO trades at ₹70.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas CONCORD.BO's P/E ratio is 159.80. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to CONCORD.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to CONCORD.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CONCORD.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, BIBCL.BO has a market cap of 674.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while BIBCL.BO trades at ₹14.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas BIBCL.BO's P/E ratio is -4.71. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to BIBCL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BIBCL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, BACPHAR.BO has a market cap of 661M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while BACPHAR.BO trades at ₹47.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas BACPHAR.BO's P/E ratio is 92.10. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to BACPHAR.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to BACPHAR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BACPHAR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ZENITHDRUG.NS has a market cap of 653.4M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ZENITHDRUG.NS trades at ₹35.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ZENITHDRUG.NS's P/E ratio is 9.11. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ZENITHDRUG.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENITHDRUG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENITHDRUG.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, GODAVARI.BO has a market cap of 645.2M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while GODAVARI.BO trades at ₹86.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas GODAVARI.BO's P/E ratio is -94.15. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to GODAVARI.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to GODAVARI.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GODAVARI.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SUNLOC.BO has a market cap of 641.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SUNLOC.BO trades at ₹61.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SUNLOC.BO's P/E ratio is 22.44. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SUNLOC.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to SUNLOC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SUNLOC.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VILINBIO.NS has a market cap of 521M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VILINBIO.NS trades at ₹36.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VILINBIO.NS's P/E ratio is 233.44. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to VILINBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check VILINBIO.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PHRMASI.BO has a market cap of 510.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PHRMASI.BO trades at ₹75.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PHRMASI.BO's P/E ratio is 2.88. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PHRMASI.BO's ROE of +1.86%. Regarding short-term risk, PARMAX.BO is more volatile compared to PHRMASI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check PHRMASI.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VISTAPH.BO has a market cap of 448.7M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VISTAPH.BO trades at ₹6.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VISTAPH.BO's P/E ratio is -5.56. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VISTAPH.BO's ROE of -0.17%. Regarding short-term risk, PARMAX.BO is less volatile compared to VISTAPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VISTAPH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VEERHEALTH.BO has a market cap of 400.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VEERHEALTH.BO trades at ₹20.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VEERHEALTH.BO's P/E ratio is 50.10. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VEERHEALTH.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to VEERHEALTH.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check VEERHEALTH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PANJON.BO has a market cap of 394.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PANJON.BO trades at ₹22.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PANJON.BO's P/E ratio is 92.00. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PANJON.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to PANJON.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check PANJON.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VRL.BO has a market cap of 342.1M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VRL.BO trades at ₹105.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VRL.BO's P/E ratio is 9.15. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VRL.BO's ROE of +0.10%. Regarding short-term risk, PARMAX.BO is less volatile compared to VRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check VRL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SHELTER.BO has a market cap of 335.4M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SHELTER.BO trades at ₹26.83.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SHELTER.BO's P/E ratio is 5.36. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SHELTER.BO's ROE of +0.12%. Regarding short-term risk, PARMAX.BO is less volatile compared to SHELTER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SHELTER.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SANDUPHQ.BO has a market cap of 322.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SANDUPHQ.BO trades at ₹30.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SANDUPHQ.BO's P/E ratio is 15.81. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SANDUPHQ.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is less volatile compared to SANDUPHQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check SANDUPHQ.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ROOPAIND.BO has a market cap of 316.4M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ROOPAIND.BO trades at ₹39.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ROOPAIND.BO's P/E ratio is 16.35. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ROOPAIND.BO's ROE of +0.11%. Regarding short-term risk, PARMAX.BO is less volatile compared to ROOPAIND.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ROOPAIND.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MEDICAPQ.BO has a market cap of 301.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MEDICAPQ.BO trades at ₹23.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MEDICAPQ.BO's P/E ratio is -6.90. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MEDICAPQ.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDICAPQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDICAPQ.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, MEDIORG.NS has a market cap of 295.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while MEDIORG.NS trades at ₹21.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas MEDIORG.NS's P/E ratio is 5.79. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is less volatile compared to MEDIORG.NS. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check MEDIORG.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TRIMURTHI.BO trades at ₹26.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TRIMURTHI.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to TRIMURTHI.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TRIMURTHI.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, GUJTERC.BO has a market cap of 257.6M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while GUJTERC.BO trades at ₹30.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas GUJTERC.BO's P/E ratio is -17.68. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to GUJTERC.BO's ROE of -0.16%. Regarding short-term risk, PARMAX.BO is less volatile compared to GUJTERC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check GUJTERC.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ANG.BO has a market cap of 252.2M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ANG.BO trades at ₹18.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ANG.BO's P/E ratio is -2.14. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ANG.BO's ROE of -0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to ANG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ANG.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, CRSTCHM.BO has a market cap of 250.6M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while CRSTCHM.BO trades at ₹77.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas CRSTCHM.BO's P/E ratio is 11.26. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to CRSTCHM.BO's ROE of +0.30%. Regarding short-term risk, PARMAX.BO is less volatile compared to CRSTCHM.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CRSTCHM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ISHITADR.BO has a market cap of 206.7M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ISHITADR.BO trades at ₹69.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ISHITADR.BO's P/E ratio is 23.27. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ISHITADR.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to ISHITADR.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ISHITADR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while CHEMOPH.BO trades at ₹130.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to CHEMOPH.BO's ROE of -0.87%. Regarding short-term risk, PARMAX.BO is less volatile compared to CHEMOPH.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check CHEMOPH.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, DECCAN.BO has a market cap of 181.2M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while DECCAN.BO trades at ₹6.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas DECCAN.BO's P/E ratio is 7.96. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECCAN.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECCAN.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ASRL.BO has a market cap of 171.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ASRL.BO trades at ₹5.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ASRL.BO's P/E ratio is 15.92. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ASRL.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to ASRL.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ASRL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SUNREST.NS has a market cap of 156.4M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SUNREST.NS trades at ₹37.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SUNREST.NS's P/E ratio is 7.81. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to SUNREST.NS. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SUNREST.NS's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ZENITHHE.BO has a market cap of 149.4M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ZENITHHE.BO trades at ₹2.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ZENITHHE.BO's P/E ratio is 34.75. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ZENITHHE.BO's ROE of +0.06%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENITHHE.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENITHHE.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, NORRIS.BO has a market cap of 127.5M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while NORRIS.BO trades at ₹13.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to NORRIS.BO's ROE of +0.08%. Regarding short-term risk, PARMAX.BO is less volatile compared to NORRIS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check NORRIS.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, CHCL.BO has a market cap of 125.2M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while CHCL.BO trades at ₹5.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas CHCL.BO's P/E ratio is -0.06. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to CHCL.BO's ROE of -0.21%. Regarding short-term risk, PARMAX.BO is more volatile compared to CHCL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check CHCL.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, EMMESSA.BO has a market cap of 120M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while EMMESSA.BO trades at ₹23.56.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas EMMESSA.BO's P/E ratio is 37.53. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to EMMESSA.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to EMMESSA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check EMMESSA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, DESHRAK.BO has a market cap of 119.7M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while DESHRAK.BO trades at ₹27.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas DESHRAK.BO's P/E ratio is 36.99. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to DESHRAK.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to DESHRAK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check DESHRAK.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ZENLABS.BO has a market cap of 119M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ZENLABS.BO trades at ₹17.37.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ZENLABS.BO's P/E ratio is -6.44. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ZENLABS.BO's ROE of -0.18%. Regarding short-term risk, PARMAX.BO is less volatile compared to ZENLABS.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check ZENLABS.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, SHAMROIN.BO has a market cap of 116.1M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while SHAMROIN.BO trades at ₹21.38.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas SHAMROIN.BO's P/E ratio is -11.56. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to SHAMROIN.BO's ROE of -0.68%. Regarding short-term risk, PARMAX.BO is more volatile compared to SHAMROIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check SHAMROIN.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, COLINZ.BO has a market cap of 109.5M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while COLINZ.BO trades at ₹44.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas COLINZ.BO's P/E ratio is 22.18. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to COLINZ.BO's ROE of +0.05%. Regarding short-term risk, PARMAX.BO is more volatile compared to COLINZ.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check COLINZ.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TRINITYLEA.BO has a market cap of 96.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TRINITYLEA.BO trades at ₹12.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TRINITYLEA.BO's P/E ratio is -405.67. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TRINITYLEA.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is more volatile compared to TRINITYLEA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TRINITYLEA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, BERLDRG.BO has a market cap of 93.3M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while BERLDRG.BO trades at ₹19.28.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas BERLDRG.BO's P/E ratio is 613.33. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to BERLDRG.BO's ROE of +0.00%. Regarding short-term risk, PARMAX.BO is less volatile compared to BERLDRG.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check BERLDRG.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, HINDBIO.BO has a market cap of 76M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while HINDBIO.BO trades at ₹7.77.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas HINDBIO.BO's P/E ratio is 49.40. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to HINDBIO.BO's ROE of +0.17%. Regarding short-term risk, PARMAX.BO is more volatile compared to HINDBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check HINDBIO.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, ADLINE.BO has a market cap of 73.1M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while ADLINE.BO trades at ₹12.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to ADLINE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check ADLINE.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, VIVANZA.BO has a market cap of 72M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while VIVANZA.BO trades at ₹1.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas VIVANZA.BO's P/E ratio is -45.00. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to VIVANZA.BO's ROE of -0.03%. Regarding short-term risk, PARMAX.BO is more volatile compared to VIVANZA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check VIVANZA.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, GANGAPHARM.BO has a market cap of 70.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while GANGAPHARM.BO trades at ₹12.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas GANGAPHARM.BO's P/E ratio is 109.09. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is more volatile compared to GANGAPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check GANGAPHARM.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TIAANC.BO has a market cap of 68.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TIAANC.BO trades at ₹6.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TIAANC.BO's P/E ratio is -67.10. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, PARMAX.BO is less volatile compared to TIAANC.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check TIAANC.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, EVOQ.BO has a market cap of 62.7M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while EVOQ.BO trades at ₹2.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas EVOQ.BO's P/E ratio is 3.55. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to EVOQ.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to EVOQ.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check EVOQ.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, KOBO.BO has a market cap of 55.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while KOBO.BO trades at ₹2.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas KOBO.BO's P/E ratio is -1.10. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, PARMAX.BO is less volatile compared to KOBO.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check KOBO.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, DECIPHER.BO has a market cap of 53.8M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while DECIPHER.BO trades at ₹5.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas DECIPHER.BO's P/E ratio is -0.67. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to DECIPHER.BO's ROE of -0.37%. Regarding short-term risk, PARMAX.BO is less volatile compared to DECIPHER.BO. This indicates potentially lower risk in terms of short-term price fluctuations for PARMAX.BO.Check DECIPHER.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, PATIDAR.BO has a market cap of 46.7M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while PATIDAR.BO trades at ₹8.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas PATIDAR.BO's P/E ratio is -17.69. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to PATIDAR.BO's ROE of -0.04%. Regarding short-term risk, PARMAX.BO is more volatile compared to PATIDAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check PATIDAR.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, TMTIND-B1.BO has a market cap of 36.2M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while TMTIND-B1.BO trades at ₹7.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas TMTIND-B1.BO's P/E ratio is 18.74. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, PARMAX.BO is more volatile compared to TMTIND-B1.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check TMTIND-B1.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, FABINO.BO has a market cap of 30.9M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while FABINO.BO trades at ₹15.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas FABINO.BO's P/E ratio is -20.14. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, PARMAX.BO is more volatile compared to FABINO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check FABINO.BO's competition here

PARMAX.BO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, PARMAX.BO stands at 94.4M. In comparison, WELCURE.BO has a market cap of 28.1M. Regarding current trading prices, PARMAX.BO is priced at ₹28.44, while WELCURE.BO trades at ₹0.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

PARMAX.BO currently has a P/E ratio of -1.86, whereas WELCURE.BO's P/E ratio is 1.09. In terms of profitability, PARMAX.BO's ROE is +2.20%, compared to WELCURE.BO's ROE of +0.32%. Regarding short-term risk, PARMAX.BO is more volatile compared to WELCURE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for PARMAX.BO.Check WELCURE.BO's competition here